These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15522649)

  • 1. Let kids be kids.
    Lancet Oncol; 2004 Nov; 5(11):641. PubMed ID: 15522649
    [No Abstract]   [Full Text] [Related]  

  • 2. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 3. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
    Prowell T
    Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
    [No Abstract]   [Full Text] [Related]  

  • 4. Anticancer therapy-induced adverse events: practicing damage control.
    Lacouture ME; Lenihan D; Wu S
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S1-3. PubMed ID: 22409299
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer drugs. Weighing the risks and benefits.
    Bren L
    FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of systemic antineoplastic drug therapy after regulatory agency approval.
    Markman M
    Oncology; 2007; 72(3-4):145-6. PubMed ID: 18087174
    [No Abstract]   [Full Text] [Related]  

  • 7. Are targeted therapies really targeted?
    Schilsky RL
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
    [No Abstract]   [Full Text] [Related]  

  • 8. Current status of oral anticancer drugs in Japan.
    Fujiwara Y
    J Clin Oncol; 1999 Oct; 17(10):3362-5. PubMed ID: 10506642
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase 1 clinical trials nursing: determining safety and side effects on the road approval.
    Lindberg D
    ONS Connect; 2012 Jul; 27(7):10-4. PubMed ID: 22855983
    [No Abstract]   [Full Text] [Related]  

  • 10. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.
    Lebwohl D; Kay A; Berg W; Baladi JF; Zheng J
    Cancer J; 2009; 15(5):386-94. PubMed ID: 19826358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hospital network in pediatric oncology].
    Doz F
    Arch Pediatr; 2006 Jun; 13(6):635-7. PubMed ID: 16697587
    [No Abstract]   [Full Text] [Related]  

  • 12. [Targeted drugs a chance for a better cure].
    Bergh J; Jonsson B
    Lakartidningen; 2010 Apr 21-27; 107(16):1071-4. PubMed ID: 20476704
    [No Abstract]   [Full Text] [Related]  

  • 13. Trend toward noninferiority trials may mean more difficult interpretation of trial results.
    Tuma RS
    J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926
    [No Abstract]   [Full Text] [Related]  

  • 14. Time to mandate data release and independent audits for all clinical trials.
    Haines IE; Gabor Miklos GL
    Med J Aust; 2011 Nov; 195(10):575-7. PubMed ID: 22106997
    [No Abstract]   [Full Text] [Related]  

  • 15. Liposomal drug formulations in cancer therapy: 15 years along the road.
    Slingerland M; Guchelaar HJ; Gelderblom H
    Drug Discov Today; 2012 Feb; 17(3-4):160-6. PubMed ID: 21983329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA approves new drug for gastrointestinal stromal tumors.
    Clin J Oncol Nurs; 2002; 6(3):124. PubMed ID: 11998599
    [No Abstract]   [Full Text] [Related]  

  • 17. [Off label drugs and pediatric hematology-oncology practices].
    Le Guyader N; Pouliquen AL; Benoit G; Leverger G
    Arch Pediatr; 2006 Sep; 13(9):1267-8. PubMed ID: 16814531
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-inferiority trials: why oncologists must remain wary.
    Burotto M; Prasad V; Fojo T
    Lancet Oncol; 2015 Apr; 16(4):364-6. PubMed ID: 25846084
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug approval triggers debate on future direction for cancer treatments.
    Frantz S
    Nat Rev Drug Discov; 2006 Feb; 5(2):91. PubMed ID: 16521324
    [No Abstract]   [Full Text] [Related]  

  • 20. Tyrannosaurus Rex revisited--will it survive?
    Eberhardt W
    Future Oncol; 2005 Apr; 1(2):141-3. PubMed ID: 16555983
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.